{"name":"Angion Biomedica Corp","slug":"angion-biomedica-corp","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2301000,"revenueGrowth":-91.9,"grossMargin":0,"rdSpend":24903000,"netIncome":-39571000,"cash":25862000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ANG-3070","genericName":"ANG-3070","slug":"ang-3070","indication":"Diabetic kidney disease","status":"phase_2"},{"name":"ANG-3777","genericName":"ANG-3777","slug":"ang-3777","indication":"Diabetic kidney disease","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ANG3070","genericName":"ANG3070","slug":"ang3070","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ANG-3070","genericName":"ANG-3070","slug":"ang-3070","phase":"phase_2","mechanism":"ANG-3070 is a tyrosine kinase inhibitor that targets angiopoietin signaling to promote vascular stabilization and tissue repair.","indications":["Diabetic kidney disease","Peripheral artery disease"],"catalyst":""},{"name":"ANG-3777","genericName":"ANG-3777","slug":"ang-3777","phase":"phase_3","mechanism":"ANG-3777 is a hepatocyte growth factor (HGF) mimetic that activates the MET receptor to promote tissue repair and regeneration.","indications":["Diabetic kidney disease","Peripheral artery disease"],"catalyst":""},{"name":"ANG3070","genericName":"ANG3070","slug":"ang3070","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFBScXRtQ0tnTHAtQ1RNeTQwUm9HcmNXWXVJUzg0NGo4b2dUVnVYSS01ekpBUlpXa1J0bDlpWlhham5ubzhYZXh4dW5yanlVR19ZSnc?oc=5","date":"2025-06-06","type":"trial","source":"endpoints.news","summary":"IPO Tracker (2021) - endpoints.news","headline":"IPO Tracker (2021)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPenlfMFp2d3A3ajZTVjhlcjdoVERQLVhqNEx1STF4M3B2MUJsVXRPV3lvTkFWRUtseF83Z2JUc1hWellFc1pPVXlLSUdJZlFvZHFhMWFKRzBSeWpjOUt3SnZKNDU0YzlJZVV4U2tPc0gtTXJCQnJIYWZWNUZjWEg3RElfWlpvSHhnQXY2TDBPTHd3MmRJZkhTMWhqaVVKSzZ5NWJGNGVHcUZTS1k?oc=5","date":"2023-06-01","type":"deal","source":"Elicio Therapeutics","summary":"Elicio Therapeutics Announces Completion of Merger with Angion Biomedica - Elicio Therapeutics","headline":"Elicio Therapeutics Announces Completion of Merger with Angion Biomedica","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOd1FvYTVLWUdKSDJJaGlRWHkwanpiZkpnWWtDSnE5NzhfQTVvTUxFMzRKS2VOTVdLM0l0UWlaRG9icHRpUmM3dDZjd01qc0JIcmhUNkZqalNjVUN3bVhmdFA0dFZwQ3lDakFKUjU2S3pMN0ttRWtPSUZKenFLODhWeWlIZzN6eHp5SGIwTXV1ZTJWaHNW?oc=5","date":"2023-01-17","type":"deal","source":"pharmaphorum","summary":"Angion stock falls after agreeing Elicio Therapeutics merger - pharmaphorum","headline":"Angion stock falls after agreeing Elicio Therapeutics merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNTnliMTZNM3l5Njh2TFEzc0tLOUdSck1IaWVkVjBzMUlfRzlXelVTQTJYOV92OGZGd1NQSlBtT2FDX0J4TjhuUHNGZzNDYkw3T3J3Qk5xWUdvMnBWT041cEpKUWQzb2tYN0FXd0ZzY2hSb2xsLVY3aldueDVyNmFSeGtBdV9JTFo2Y0s3UmZ1a1pLM2VNUTVtaEhtZ3I2RWJ3eUE?oc=5","date":"2022-08-30","type":"trial","source":"globaldata.com","summary":"Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - globaldata.com","headline":"Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Upda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQTlRCYlVpUWpsQmVkQmEyOGJaZ3ktODJmXzlqZ0I0TXdKTnQ1ZWNvTnNOU185YUZGZ1MycDRONVhSMXdKTlBwM2V3NXgzQlIzQzhuS0h6V2RIS1FlVm03VzVfZlNhWUk1bWJyajBNZEd1dG90Rl9WVFNDc0dVdmRJT2J0SkdzYmkzS0VUc2J1ajJhOGsza1cwcmI2UDdnT1JSY2N2M0JlSTBnVTZlVllrSDhreW5iU09yQXc?oc=5","date":"2022-07-26","type":"pipeline","source":"Fierce Biotech","summary":"Angion hangs up 'for sale' sign, stops drug development work after flops force search for exit - Fierce Biotech","headline":"Angion hangs up 'for sale' sign, stops drug development work after flops force search for exit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxPUkc5aVlsaGUzX2FiMWI2cGsyOGUyRkRpdmhtOTFtSGdWUi1BVEhOSXA2RV9xT1FQMEo1YnZ1MFdvMkFrYk5DU1QxT0RfT2UwZlA1NllUTXloNzNENmM4MjVQc29iWWNYMF9VZXM3OW9sZWhueGFYYVJ5S0o1cGt1Vlh1NU9NczNtLXBGSkZjQTFSX1N2QVd1SDdxandrclFfU3g2NFJ0OHk1VVFVd2pGRXVVSE1OUVVVVkF5TDhVcEt2N2JVT1RTV3Zqd3JMblh2WVV5ZHBwZ192TGdXcE1vZDA0NXRHaWRDTmJKcmNka21GV2hGNEY4TmR1WWwxMTAxRF81TkVTbG1oV1pWX3padUlsYVQ3aElnemQ3ak5mczc?oc=5","date":"2021-12-10","type":"trial","source":"Via TT","summary":"Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury - Via TT","headline":"Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNVnJZSTBFVVVhemVPLVRVTW90UFFJQnpmLVZENHl5dldOMFRnUTBQYjZEYTl1RVJfSE1HYTMyU3o2VldXSVRUUnFuRmtoSmlUYmJUTzJCV0N4MjBuOGpnNG5hdXdURkl5aEM0b3ZyS1FpUTM1VGVjMnNRUTV6ajBOX3U0R09ZWkZLaEwtMkVGWF82dW9DeUVNblRZRExoUlFwejhaNUk3dVZNUm9KZ2RoWm5kbktoaHVVOFVSTHRwT2ZZYnJidXowVzQ4Vmh6cUd1UmpHbDBxSVV2eEN0WjdzcGRCd2N3cUs5Z2VIWVJn?oc=5","date":"2020-11-09","type":"deal","source":"GlobeNewswire","summary":"Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications - GlobeNewswire","headline":"Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9YX21aa2ZyY2tPckhuZ2VoVkJKV2M4b2NNVkhyb2ZlVVZ2YjhTbVp1VGc3YnZRNElLRXRHaUpyeEQ4eGlIRHZGdFh3V29EMW1HVXFXdFlCcWUwc0xHV0xhNHdLQ2p1SmM?oc=5","date":"2020-05-29","type":"pipeline","source":"Long Island Business News","summary":"ChemRX plans Uniondale move - Long Island Business News","headline":"ChemRX plans Uniondale move","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":1,"phase_3":1,"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":2301000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":2301000,"period":"2022-12-31"},{"value":28312000,"period":"2021-12-31"},{"value":28312000,"period":"2021-12-31"},{"value":2880000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":24903000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-39571000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":25862000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}